TLR7 ligation augments haematopoiesis in Rps14 (uS11) deficiency via paradoxical suppression of inflammatory signalling and enhanced differentiation
O. C. Pena, A. Lubin, J. Rowell, C. A. Hockings, Y. Jung, Y. Hoade, P. Dace, L. E. Valdivia, K. Tuschl, C. Böiers, M. C. Virgilio, S. Richardson, E. M. Payne
This study identifies imiquimod, a TLR7 agonist, as a therapeutic for MDS by enhancing haematopoiesis through paradoxical anti-inflammatory effects and increased differentiation.
bioRxiv · Jul 6, 2020Cancer Biology